6 results on '"Zhang, Hanwen"'
Search Results
2. RETRACTED ARTICLE: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis
- Author
-
Liang, Yiran, Song, Xiaojin, Li, Yaming, Chen, Bing, Zhao, Wenjing, Wang, Lijuan, Zhang, Hanwen, Liu, Ying, Han, Dianwen, Zhang, Ning, Ma, Tingting, Wang, Yajie, Ye, Fangzhou, Luo, Dan, Li, Xiaoyan, and Yang, Qifeng
- Published
- 2020
- Full Text
- View/download PDF
3. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis
- Author
-
Liang, Yiran, Song, Xiaojin, Li, Yaming, Chen, Bing, Zhao, Wenjing, Wang, Lijuan, Zhang, Hanwen, Liu, Ying, Han, Dianwen, Zhang, Ning, Ma, Tingting, Wang, Yajie, Ye, Fangzhou, Luo, Dan, Li, Xiaoyan, and Yang, Qifeng
- Subjects
PTBP3 ,Mice, Nude ,Apoptosis ,Breast Neoplasms ,lcsh:RC254-282 ,LncRNA BCRT1 ,Mice ,Breast cancer ,Biomarkers, Tumor ,Tumor Cells, Cultured ,Animals ,Humans ,miR-1303 ,Cell Proliferation ,Mice, Inbred BALB C ,Progression ,Research ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Xenograft Model Antitumor Assays ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,Disease Progression ,Female ,RNA, Long Noncoding ,Polypyrimidine Tract-Binding Protein - Abstract
Background Long noncoding RNAs (lncRNAs) play crucial roles in tumor progression and are aberrantly expressed in various cancers. However, the functional roles of lncRNAs in breast cancer remain largely unknown. Methods Based on public databases and integrating bioinformatics analyses, the overexpression of lncRNA BCRT1 in breast cancer tissues was detected and further validated in a cohort of breast cancer tissues. The effects of lncRNA BCRT1 on proliferation, migration, invasion and macrophage polarization were determined by in vitro and in vivo experiments. Luciferase reporter assay and RNA immunoprecipitation (RIP) were carried out to reveal the interaction between lncRNA BCRT1, miR-1303, and PTBP3. Chromatin immunoprecipitation (ChIP) and RT-PCR were used to evaluate the regulatory effect of hypoxia-inducible factor-1α (HIF-1α) on lncRNA BCRT1. Results LncRNA BCRT1 was significantly upregulated in breast cancer tissues, which was correlated with poor prognosis in breast cancer patients. LncRNA BCRT1 knockdown remarkably suppressed tumor growth and metastasis in vitro and in vivo. Mechanistically, lncRNA BCRT1 could competitively bind with miR-1303 to prevent the degradation of its target gene PTBP3, which acts as a tumor-promoter in breast cancer. LncRNA BCRT1 overexpression could promote M2 polarization of macrophages, mediated by exosomes, which further accelerated breast cancer progression. Furthermore, lncRNA BCRT1 was upregulated in response to hypoxia, which was attributed to the binding of HIF-1α to HREs in the lncRNA BCRT1 promoter. Conclusions Collectively, these results reveal a novel HIF-1α/lncRNA BCRT1/miR-1303/PTBP3 pathway for breast cancer progression and suggest that lncRNA BCRT1 might be a potential biomarker and therapeutic target for breast cancer.
- Published
- 2020
4. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance.
- Author
-
Zhang, Xinyi, Xie, Kai, Zhou, Honghua, Wu, Yuwei, Li, Chan, Liu, Yating, Liu, Zhaoya, Xu, Qian, Liu, Shuang, Xiao, Desheng, and Tao, Yongguang
- Subjects
NON-coding RNA ,CANCER treatment ,RNA ,LUNG cancer ,STOMACH cancer - Abstract
As the standard treatments for cancer, chemotherapy and radiotherapy have been widely applied to clinical practice worldwide. However, the resistance to cancer therapies is a major challenge in clinics and scientific research, resulting in tumor recurrence and metastasis. The mechanisms of therapy resistance are complicated and result from multiple factors. Among them, non-coding RNAs (ncRNAs), along with their modifiers, have been investigated to play key roles in regulating tumor development and mediating therapy resistance within various cancers, such as hepatocellular carcinoma, breast cancer, lung cancer, gastric cancer, etc. In this review, we attempt to elucidate the mechanisms underlying ncRNA/modifier-modulated resistance to chemotherapy and radiotherapy, providing some therapeutic potential points for future cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA.
- Author
-
Wang, Wei, Hu, Wentao, Wang, Ya, An, Yong, Song, Lei, Shang, Panfeng, and Yue, Zhongjin
- Subjects
RENAL cancer ,NON-coding RNA ,CANCER cells ,CANCER cell proliferation ,CARCINOGENESIS ,BLADDER cancer - Abstract
Background: Accumulating literatures have indicated that long non-coding RNAs (lncRNAs) are potential biomarkers that play key roles in tumor development and progression. Urothelial cancer associated 1 (UCA1) is a novel lncRNA that acts as a potential biomarker and is involved in the development of cancers. However, the molecular mechanism of UCA1 in renal cancer is still needed to further explore. Methods: The relative expression level of UCA1 was determined by Real-Time qPCR in a total of 88 patients with urothelial renal cancer and in different renal cancer cell lines. Loss-of-function experiments were performed to investigate the biological roles of UCA1 and miR-182-5p on renal cancer cell proliferation, migration, apoptosis and tumorigenicity. Comprehensive transcriptional analysis, dual-luciferase reporter assay and western blot etc. were performed to explore the molecular mechanisms underlying the functions of UCA1. Results: In this study, we found that UCA1 was significantly up-regulated in renal cancer. Moreover, increased UCA1 expression was positively correlated with differentiation and advanced TNM stage. Further experiments demonstrated that knockdown of UCA1 inhibited malignant phenotypes and Notch signal path of renal cancer cells, and miR-182-5p was reverse function as UCA1. UCA1 functioned as a miRNA sponge to positively regulate the expression of Delta-like ligand 4(DLL4) through sponging miR-182-5p and subsequently promoted malignant phenotypes of renal cancer cells, thus UCA1 playing an oncogenic role and miR-182-5p as an antioncogenic one in renal cancer pathogenesis. Conclusion: UCA1-miR-182-5p-DLL4 axis is involved in proliferation and progression of renal cancer. Thus, this study demonstrated that UCA1 plays a critical regulatory role in renal cancer cell and UCA1 may serve as a potential diagnostic biomarker and therapeutic target of renal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Roles of circRNAs in the tumour microenvironment.
- Author
-
Zhang, Qiuge, Wang, Weiwei, Zhou, Quanbo, Chen, Chen, Yuan, Weitang, Liu, Jinbo, Li, Xiaoli, and Sun, Zhenqiang
- Subjects
PHYSIOLOGICAL control systems ,TUMORS ,CANCER ,CIRCULAR RNA ,NON-coding RNA - Abstract
The tumour microenvironment (TME) constitutes the area surrounding the tumour during its development and has been demonstrated to play roles in cancer-related diseases through crosstalk with tumour cells. Circular RNAs (circRNAs) are a subpopulation of endogenous noncoding RNAs (ncRNAs) that are ubiquitously expressed in eukaryotes and have multiple biological functions in the regulation of cancer onset and progression. An increasing number of studies have shown that circRNAs participate in the multifaceted biological regulation of the TME. However, details on the mechanisms involved have remained elusive until now. In this review, we analyse the effects of circRNAs on the TME from various perspectives, including immune surveillance, angiogenesis, hypoxia, matrix remodelling, exo-circRNAs and chemoradiation resistance. Currently, the enormous potential for circRNA use in targeted therapy and as noninvasive biomarkers have drawn our attention. We emphasize the prospect of targeting circRNAs as an essential strategy to regulate TME, overcome cancer resistance and improve therapeutic outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.